Piper Sandler analyst issues NEUTRAL recommendation for MFIN on October 2, 2026 10:59AM ET. The previous analyst recommendation was Neutral.MFIN was trading at $11.92 at issue of the analyst recommendation.The overall analyst consensus : HOLD.Current analyst recommendations are : 4 - Buy, 5 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice...
Needham analyst issues BUY recommendation for STTK on October 2, 2026 11:05AM ET. The previous analyst...
from Guggenheim issued a price target of $5.00 for FHTX on 2026-10-02 10:49:43.The adjusted price target...
Robert Driscoll from Wedbush issued a price target of $2.00 for FHTX on 2026-10-02 10:49:02.The adjusted...
from Guggenheim issued a price target of $26.00 for SGMT on 2026-10-02 10:47:16.The adjusted price target...
from Guggenheim issued a price target of $5.00 for FHTX on 2026-10-02 10:49:43.The adjusted price target was set to $5.00.At the time of the announcement, FHTX was trading at $2.92.The...
Robert Driscoll from Wedbush issued a price target of $2.00 for FHTX on 2026-10-02 10:49:02.The adjusted price target was set to $2.00.At the time of the announcement, FHTX was trading...
from Guggenheim issued a price target of $26.00 for SGMT on 2026-10-02 10:47:16.The adjusted price target was set to $26.00.At the time of the announcement, SGMT was trading at $9.37.The...
Hal Goetsch from B.Riley Financial issued a price target of $8.05 for PRTH on 2026-10-02 06:44:00.The adjusted price target was set to $8.05.At the time of the announcement, PRTH was...
Roger Song from Jefferies issued a price target of $150.00 for NKTR on 2026-10-01 18:22:36.The adjusted price target was set to $150.00.At the time of the announcement, NKTR was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
